Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Myocardial Infarction in a Patient With Multiple Sclerosis After Receiving Natalizumab Publisher Pubmed



Darki A1 ; Masoumi P1 ; Soleimani A2 ; Naser Moghadasi A2
Authors

Source: Multiple Sclerosis and Related Disorders Published:2018


Abstract

Natalizumab is among the most effective drugs for controlling multiple sclerosis (MS). The most important side effect of this drug is progressive multifocal leukoencephalopathy, although some other complications are increasingly reported in literature such as meningitis and encephalitis. Here, a patient with MS who has suffered from myocardial infarction (MI) after the injection of natalizumab is introduced. © 2018
Related Docs
View other Related Docs
1. Effectiveness and Safety of Switching From Fingolimod and Natalizumab to Rituximab in Patients With Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
2. Tumefactive Demyelinating Lesions in a Patient With Multiple Sclerosis Developed Two Days After the Injection of Rituximab, Acta neurologica Taiwanica (2020)
3. Tumefactive Demyelinating Lesions in a Patient With Multiple Sclerosis Developed Two Days After the Injection of Rituximab, Acta Neurologica Taiwanica (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (7)
Abdolreaza Naser Moghadasi (5)
Other Related Docs
4. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
5. Efficacy and Safety of Natalizumab Extended Interval Dosing, Multiple Sclerosis and Related Disorders (2018)
6. The Prevalence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Under Treatment With Natalizumab (Tysabri): A Systematic Review and Meta-Analysis, International Journal of Preventive Medicine (2023)
7. Investigation of the Safety of Live Attenuated Varicella-Zoster Virus Vaccination in Patients With Relapse-Remitting Multiple Sclerosis Treated With Natalizumab: A Case Series and Review of the Literature, Multiple Sclerosis and Related Disorders (2023)
8. Evaluating the Efficacy and Safety of Zytuxtm (Rituximab, Aryogen Pharmed) in Iranian Multiple Sclerosis Patients: An Observational Study, Multiple Sclerosis and Related Disorders (2019)
9. Monoclonal Antibodies in Multiple Sclerosis Treatment, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
10. Natalizumab in Multiple Sclerosis: Discontinuation, Progressive Multifocal Leukoencephalopathy and Possible Use in Children, Expert Review of Neurotherapeutics (2015)
11. Safety and Effectiveness Assessment of Intravenous Immunoglobulin in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis, Medical Journal of the Islamic Republic of Iran (2016)
12. Adverse Side Effects of Glatiramer Acetate and Interferon Beta-1A in Patients With Multiple Sclerosis: A Systematic Review of Case Reports, Current Journal of Neurology (2023)
13. Is Monkeypox a Concern in Multiple Sclerosis Patients? a Letter to Editor, Archives of Academic Emergency Medicine (2022)
14. Incidence of Seroconversion and Sero-Reversion in Patients With Multiple Sclerosis (Ms) Who Had Been Treated With Natalizumab: A Systematic Review and Meta-Analysis, Journal of Clinical Neuroscience (2020)
15. The Efficacy and Safety of Oral Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2020)
16. Immunomodulatory Characteristics of Mesenchymal Stem Cells and Their Role in the Treatment of Multiple Sclerosis, Cellular Immunology (2015)
17. The Effects and Side Effects of Laquinimod for the Treatment of Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis of Clinical Trials, European Journal of Clinical Pharmacology (2020)
18. Stem Cell Therapy for Multiple Sclerosis, Cochrane Database of Systematic Reviews (2018)
19. Clinical and Radiological Activity After Extended Interval and Standard Interval Dosing of Ocrelizumab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurological Sciences (2025)
20. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)